Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.054.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -53.73% | 167.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.07% | 75.73% | |||
| Operating Income | 36.07% | -75.73% | |||
| Income Before Tax | 33.31% | -98.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.31% | -98.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.31% | -98.92% | |||
| EBIT | 36.07% | -75.73% | |||
| EBITDA | 37.30% | -84.08% | |||
| EPS Basic | 36.85% | -88.14% | |||
| Normalized Basic EPS | 26.71% | -60.73% | |||
| EPS Diluted | 34.81% | -88.14% | |||
| Normalized Diluted EPS | 26.71% | -60.73% | |||
| Average Basic Shares Outstanding | 5.64% | 5.70% | |||
| Average Diluted Shares Outstanding | 5.64% | 5.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||